Regulated information

Reports very good first half, confirming that 2007 performance is set to surpass targets

Presentation of Vétoquinol’s results for the first half of 2007

2007 Half year results

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

Vétoquinol to market and distribute Vetprofen in the United States

Vétoquinol announces opening of its first decentralized R&D center in Canada

Revenue grows by 10.3% in 2007, to €233.4 M

KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french)

VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe

Earnings for 2007 attest to strength of business growth model

The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance
indicators, ahead of its medium-term targets. According to the most recent statistics published by Vetnosis, this substantial rise in revenue has lifted Vétoquinol to third place
worldwide.

Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis

Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment.